"ALPHA RECHERCHE CLINIQUE de Val-Bélair et de Lebourneuf se veulent deux centres d’expertises spécialisés en recherche clinique à Québec. Nos centres ce sont dotés d’un mandat bien spécifique : offrir à la population la possibilité de recevoir un suivi médical de haute qualité à travers des protocoles de recherche consciencieusement sélectionnés par notre équipe. Ces projets sont bien sûr soumis à un Comité d’Éthique et aux Autorités Réglementaires. Notre équipe d’infirmières et de médecins, vous accueillent dans l’ambiance chaleureuse de nos deux centres. Nos protocoles de recherche touchent des problémes de santé telles que : hypertension contraception diabète douleur chronique arthrose post-infarctus maladie Alzheimer et autres"

During the past decade, Alpha Recherche Clinique conducted 29 clinical trials. In the 10-year time frame, 29 clinical trials started and 16 clinical trials were completed, i.e. on average, 55.2% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 8 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Alpha Recherche Clinique" #1 sponsor was "Pfizer" with 14 trials, followed by "Hoffmann-La Roche" with 6 trials sponsored, "Eli Lilly and Company" with 3 trials sponsored, "Janssen Research & Development, LLC" with 3 trials sponsored and "Bayer" with 3 trials sponsored. Other sponsors include 10 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Alpha Recherche Clinique" #1 collaborator was "Brigham and Women's Hospital" with 1 trials as a collaborator, "Hoffmann-La Roche" with 1 trials as a collaborator, "ICON Clinical Research" with 1 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator and "Premier Research Group plc" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Alpha Recherche Clinique" are "Alzheimer Disease" (8 trials), "Obesity" (3 trials), "Alzheimer's Disease" (2 trials), "Depressive Disorder, Major" (2 trials) and "Diabetes Mellitus, Type 2" (2 trials). Many other conditions were trialed in "Alpha Recherche Clinique" in a lesser frequency.

Most popular intervention types in "Alpha Recherche Clinique" are "Drug" (37 trials), "Biological" (7 trials), "Other" (5 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (29 trials), "Gantenerumab" (5 trials), "Aticaprant" (2 trials), "PF-05221304" (2 trials) and "Asunaprevir (ASV)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Alpha Recherche Clinique" are 40 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Alpha Recherche Clinique". undefined are not yet recruiting, 6 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 21 completed trials in Alpha Recherche Clinique, 1 suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Alpha Recherche Clinique, 1 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 30 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".